Wells Fargo & Company Tyra Biosciences, Inc. Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding TYRA
# of Institutions
80Shares Held
43.3MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA10.4MShares$171 Million2.51% of portfolio
-
Boxer Capital, LLC San Diego, CA6.45MShares$106 Million5.73% of portfolio
-
Bvf Inc San Francisco, CA4.66MShares$76.5 Million2.28% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.41MShares$72.4 Million97.89% of portfolio
-
Nextech Invest Ag4.06MShares$66.6 Million12.24% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $689M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...